Peer reviewed, first literature publication of icovamenib achieving Complete Response in NUP98r Acute Myeloid Leukemia Patient
PARTNERING
Partnerships
All our assets are in-house designed, developed, and wholly owned by Biomea Fusion Inc. While we are advancing the pipeline candidates, we remain open to future partnerships for current development candidates and/or additional targets leveraging our novel FUSION system.
If you would like to contact the team, please use the form below. You may also reach out directly:Ramses Erdtmann, COO & President of Biomea Fusion.